Abstract:Abstract Current approaches for colorectal cancer (CRC) chemoprevention, including the use of NSAID, have tended predominantly toward modulating tumorigenic pathways rather than eliminating large number of premalignant or subclinical malignant cells. This tendency reflects the effort to keep toxicity to a minimum. The effectiveness of such modulative agents, however, is generally low to moderate, and long-term treatment is often required to produce any significant preventive benefit. In turn, long-term therapy frequently produces unanticipated adverse effects even with agents generally thought to have low toxicity. To overcome the challenges in current chemoprevention, we propose to perform chemoprevention in a therapy-like fashion, i.e., through short-term and intermittent treatments. The concept underlying this approach is based on elimination of large number of premalignant cells (to a greater degree than sought generally in chemoprevention) via short-tem treatments by specifically targeting genetic or epigenetic changes in premalignant cells. Periodically reducing or eliminating the number of premalignant cells through a series of noncontinuous/intermittent short-term therapies potentially will significantly reduce the chance of accumulation multiple mutations in same cells, which is required to generate malignant clones. This will delay or even completely prevent cancer in long-term. In this way, the potential side effects and costs often associated with long-term treatment could be minimized and controlled. In a recent paper (Nature. 2010 Apr 15; 464(7291): 1058-61. Epub 2010 Mar 28), we reported the development of a novel therapy-like chemoprevention procedure for CRC. This procedure is based on our finding that a deficiency in the adenomatous polyposis coli (APC) gene and subsequent activation of β-catenin lead to the repression of cellular caspase-8 inhibitor cFLIP expression through activation of c-Myc, and that all-transretinyl acetate (RAc) independently upregulates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptors and represses decoy receptors. Thus, the combination of TRAIL and RAc induces apoptosis in APC-deficient premalignant cells without affecting normal cells in vitro. In addition, we demonstrate that short-term and noncontinuous TRAIL and RAc treatment induces apoptosis specifically in intestinal polyps, strongly inhibits tumor growth, and promotes survival in ApcMin mice. We further show that TRAIL and RAc induce significant cell death in human colon polyps in organ culture in vitro, providing a potentially selective therapeutic approach for CRC chemoprevention by targeting APC-deficient cells for apoptosis. This study demonstrated the feasibility, efficacy, and potential tolerability of therapy-like chemoprevention in an in vivo preclinical setting. Progress toward a clinical trial will be discussed. Citation Information: Cancer Prev Res 2010;3(12 Suppl):CN13-05.

Traditional Chinese medicine (Xiaoai Jiedu Decoction) as an adjuvant treatment for prevention new colorectal adenomatous polyp occurrence in post-polypectomy: Study protocol for a randomized controlled trial.

Efficacy and Safety of Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence in Patients with Stage IIIB/IIIC Colon Cancer: Study Protocol for a Multicentre, Randomized Controlled Trial

Sijunzi decoction granules in the prevention and treatment of recurrence of colorectal adenoma: Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial

Berberine Hydrochloride for the Prevention of Colorectal Adenomas: A Double-blind, Randomised Controlled Multicenter Clinical Trial

A Randomized Controlled Trial of CAPEOX Vs Observation in Patients with Early-Stage Colorectal Cancer with Positive MRD after Curative Surgery (CAREME).

Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study.

Impact of preprocedure simethicone on adenoma detection rate during colonoscopy: a multicenter, endoscopist-blinded randomized controlled trial.

A Presurgical Study of Curcumin Combined with Anthocyanin Supplements in Patients with Colorectal Adenomatous Polyps

The Safety and Efficacy of Immune Checkpoint Inhibitor in Combination with FOLFOX As Neoadjuvant/adjuvant Therapy in Patients with Locally Advanced Colon Cancer.

Effect of Preoperative Hepatic and Regional Arterial Chemotherapy on Metachronous Liver Metastasis after Curative Colorectal Cancer Resection: A Prospective, Multicenter, Randomized Controlled Trial

Effect of Jianpi Bushen Sequential Formula on Adjuvant Chemotherapy of Colon Cancer: Study Protocol for a Randomized Controlled Trial

CapeOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Resectable Colon Cancer: Protocol for a Two-Period Randomised Controlled Phase III Trial.

Efficacy and safety of traditional Chinese medicine decoction combined with chemotherapy in the treatment of advanced colorectal cancer

Efficacy and safety of Shenbai Granules for recurrent colorectal adenoma: A multicenter randomized controlled trial

Effect of PRM1201 Combined With Adjuvant Chemotherapy on Preventing Recurrence and Metastasis of Stage III Colon Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

How to prophylactically alleviate postembolization syndrome following transarterial chemoembolization?: Protocol of a double blinded, randomized, placebo-controlled trial

A clinical study of Yiqi Huayu Jiedu decoction reducing the risk of postoperative gastric cancer recurrence and metastasis: Study protocol for a randomized controlled trail

Efficacy of Linaclotide in Combination with Polyethylene Glycol for Bowel Preparation in Chinese Patients Undergoing Colonoscopy Polypectomy: Protocol for a Randomised Controlled Trial.

Exploring the mechanism of Tengli Kangliu Decoction in the prevention and treatment of colorectal cancer precancerous based on network pharmacology

Abstract CN13-05: A Novel Approach for Colorectal Cancer Chemoprevention by Targeting APC-deficient Cells for Apoptosis

Inflammatory and Metabolic Biomarker Assessment in a Randomized Presurgical Trial of Curcumin and Anthocyanin Supplements in Patients with Colorectal Adenomas